U.S. FDA extends review of Exelixis’ cancer drug

IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment.

US FDA extends review of Exelixis’ cancer drug - Regional Media News

Sept 11 (Reuters) - The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday. The regulator will now make its decision by March 3, 2027. Shares of [...]

U.S. FDA extends review of Exelixis’ cancer drug

Sept 11 (Reuters) - The U.S. Food and Drug Administration has ​extended the ‌review of Exelixis' experimental colorectal cancer drug combination by three months, ‌the ​company said ⁠in a filing ⁠on Friday. The regulator will now make its decision by Ma...

FDA extends review of Exelixis' colorectal cancer drug candidate

California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data led to a three-month extension in the agency's review, the ...

Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment. The post Exelixis, An IBD 50…